GLS and pancreatic neoplasm: Coadministration of a glutaminase inhibitor with gemcitabine also abrogated MUC5AC (Mucin 5AC)-mediated gemcitabine resistance in mouse and human pancreatic cancers, providing a new target for future immunotherapy (47).